Analyst Price Targets — CASI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2024 7:22 am | Sean Lee | H.C. Wainwright | $6.00 | $3.26 | StreetInsider | CASI Pharmaceuticals (CASI) PT Lowered to $6 at H.C. Wainwright |
| August 15, 2022 10:29 am | — | H.C. Wainwright | $12.00 | $4.02 | Benzinga | HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Adjusts PT to $12 (1-for-10 reverse stock split) |
Latest News for CASI
CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) and Siga Technologies (NASDAQ: SIGA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability. Insider and Institutional Ownership 22.2% of CASI
CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / February 25, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that it has received a determination letter from the Hearings Panel (the "Panel") of The Nasdaq…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CASI.
U.S. House Trading
No House trades found for CASI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.